Loading clinical trials...
Loading clinical trials...
Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients
Conditions
Interventions
Anti-SARS-CoV-2 mAb
Locations
4
Canada
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Hôpital Montfort
Ottawa, Ontario, Canada
Michael Garron Hospital
Toronto, Ontario, Canada
Start Date
February 12, 2021
Primary Completion Date
January 31, 2022
Completion Date
January 31, 2022
Last Updated
April 19, 2023
NCT07189936
NCT04525716
NCT03188796
NCT04527315
NCT05013632
NCT06355232
Lead Sponsor
University of Calgary
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions